AMENDMENTS TO THE CLAIMS

The following Listing of Claims replaces all prior versions, and listings, of claims in this Application.

LISTING OF CLAIMS

1. (currently amended) An isolated humanized antibody that immunoreacts with an epitope present on human tissue factor ("TF") ~~TF~~ and inhibits the binding of human coagulation factor VIIa to human TF.

2. (currently amended) The isolated humanized antibody of claim 1, wherein the complimentarity determining region ("CDR") ~~CDR~~ amino acid sequences of the humanized antibody are derived from a parent monoclonal antibody.

3. (original) The isolated humanized antibody of claim 2, wherein the parent monoclonal antibody is a mouse monoclonal antibody.

4. (original) The isolated humanized antibody of claim 1, wherein the humanized antibody is a Fab fragment.

5. (original) The isolated humanized antibody of claim 1, wherein the humanized antibody is a $F(ab)_2$ fragment.

6. (original) The isolated humanized antibody of claim 1, wherein the humanized antibody is a $F(ab')_2$ fragment.

7. (original) The isolated humanized antibody of claim 1, wherein the humanized antibody is a single chain Fv fragment.

8. (original) The isolated humanized antibody of claim 1, wherein the humanized antibody has a K_d for binding to human TF of from about 10^{-15} to about 10^{-8} M.

9. (original) The isolated humanized antibody of claim 8, wherein the humanized antibody has a K_d for binding to human TF of from about 10^{-15} to about 10^{-10} M.

10. (original) The isolated humanized antibody of claim 9, wherein the humanized antibody has a K_d for binding to human TF of from about 10^{-15} to about 10^{-12} M.

11. (original The isolated humanized antibody of claim 1, wherein the human framework amino acid sequences of the humanized antibody are derived from a human antibody that immunoreacts with a second epitope present on human TF.

12. (original) The isolated humanized antibody of claim 11, wherein the second epitope comprises an amino acid residue at a particular position of human TF that also is comprised within the epitope.

13. (original) The isolated humanized antibody of claim 12, wherein the amino acid residue at a particular position of human TF is selected from the group consisting of Trp45, Lys46, and Tyr94.

14. (original) The isolated humanized antibody of claim 11, wherein the epitope or second epitope comprises an amino acid residue selected from the group consisting of Trp45, Lys46, and Tyr94.

15. (original) A pharmaceutically acceptable composition comprising a therapeutically effective amount of the isolated humanized antibody of claim 1.

16. (original) A pharmaceutically acceptable composition comprising a therapeutically effective amount of the isolated humanized antibody of claim 12.

17. (withdrawn) A method for treating a FVIIa/TF related disorder in a human comprising administering a therapeutically effective amount of a humanized antibody that immunoreacts with an epitope on human TF and inhibits the binding of human coagulation factor VIIa to human TF.

18-29. cancelled

30. (currently amended) A cell that produces a humanized antibody that immunoreacts with an epitope on human tissue factor ("TF") ~~TF~~ and inhibits the binding of human coagulation factor VIIa to human TF.

31. (original) The cell of claim 30, wherein the cell is a mammalian cell.

32. (currently amended) The cell of claim 30, wherein the cell is a cell derived from a cell line selected from the group consisting of CHO, BHK, HEK293, P3X63-Ag8, P3X63-AG8.653, PERC6, NS0, YB2/0, P3/NS1-Ag4-1 (NS-1), Sp2/0-Agl4 and S194/5.XXO.Bu.1.

33. (original) An isolated humanized antibody that immunoreacts with an epitope on a protein, wherein the human framework amino acid sequences of the humanized antibody are derived from a human antibody that immunoreacts with a second epitope on the protein and the second epitope comprises an amino acid residue at a particular position of the protein that also is comprised within the epitope.